ClinicalTrials.gg
CompletedNCT04743570Updated Apr 21, 2023

Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute Pancreatitis

A Phase 2/3 interventional study of Placebo treatment and Methylnaltrexone treatment in Acute Pancreatitis, sponsored by Asbjørn Mohr Drewes. Completed at 4 sites in Denmark. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Asbjørn Mohr Drewes · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Pancreatitis with a site in Denmark — 3 open to participants now, 4 under way, 1 of them phase 3. Pancreatitis · Denmark.

Started
2021
with 1 other
Phase 2/3
2 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
2 of 11
Asbjørn Mohr Drewes

Among the 11 studies in Pancreatitis with a site in Denmark, this one is one of 2 that started in 2021, is one of 2 in phase 2/3, and was the 6th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

3 of the 11 studies in Pancreatitis with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pancreatitis with a site in Denmark, or all of them as a file.
02

Study summary

This study will investigate the effect of peripheral acting opioid antagonist (PAMORA) on the disease course of patients with acute inflammation of the pancreas (acute pancreatitis). The study will be conducted by treating hospitalized patients with acute pancreatitis with a PAMORA (methylnaltrexone).

Read the detailed description

In this study, the effects of peripheral acting µ-opioid receptor antagonists (PAMORA) on disease development and progression in patients with acute pancreatitis (AP) will be investigated. Patients with AP will be administered Methylnaltrexone (Relistor®) intravenously. This medication is defined as the investigational product. Relistor® is approved and sold on the Danish marked for treatment of opioid-induced constipation. This PAMORA have not previously been investigated in patients with pancreatitis. The dose regimes for this study will be according to label. It has previously been shown, in patients with opioid-induced obstipation and healthy subjects, that opioid antagonism incl. PAMORA treatment increases gut motility, relaxes gastrointestinal sphincters, increases the intestinal water content and improves the immune response, without affecting analgesia. The affinity of PAMORAs to the µ-opioid receptors is much stronger than opioid analgesics. Therefore, they as antagonists have the potential to counteract the harmful effects of opioids on the gut mucosa, bacterial translocation and inflammation despite the high levels of exogenous opioids present in patients with pancreatitis. PAMORAs do not cross the blood-brain barrier and consequently do not interfere with analgesia or other central effects of opioids.

We hypothesize that treatment with the PAMORA methylnaltrexone will antagonize the harmful effects of opioids without reducing analgesia in patients with AP and hence reduce disease severity and improve clinical outcomes. If successful, this sub-study will for the first time document the effects of a targeted pharmacotherapy in AP with the potential benefit of improved patient outcomes.

03

Conditions studied

  • Acute Pancreatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed before any study specific procedures
  • Able to read and understand Danish
  • Male or female age between 18 and 80 years
  • The researcher believes that the participant understands what the study entails, is capable of following instructions, can attend when needed, and is expected to complete the study
  • The investigator will ensure that fertile female participants have a negative pregnancy test before treatment initiation and use during the study period. The following methods of contraception, if properly used, are generally considered reliable: oral contraceptives, patch contraceptives, injection contraceptives, vaginal contraceptive ring, intrauterine device, surgical sterilization (bilateral tubal ligation), vasectomized partner, double barrier (condom and pessary), or sexual abstinence. Methods of contraception will be documented in the source documents
  • At least two of the following criteria need to be fulfilled to establish a diagnosis of AP (according to the revised Atlanta criteria (16)): i) abdominal pain consistent with AP (acute onset of a persistent, severe, epigastric pain often radiating to the back); ii) serum amylase activity at least three times greater than the ; and iii) characteristic findings of AP on diagnostic imaging
  • Predicted moderate or severe AP based on 2 or more systemic inflammatory response syndrome criteria upon admission

Exclusion criteria

Exclusion Criteria:

  • Definitive chronic pancreatitis according to the M-ANNHEIM criteria
  • Known allergy towards study medication
  • Known or suspected major stenosis or perforation of the intestines
  • Known or suspected abdominal cancer (incl. intestine, pancreas and the biliary tree)
  • Pre-existing renal insufficiency (defined as habitual estimated below 45)
  • Severe pre-existing comorbidities (assessed by investigator upon inclusion)
  • Severe non-pancreaticobiliary infections or sepsis caused by non-pancreaticobiliary disease
  • class B or C liver cirrhosis
  • Females that are currently lactating
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Placebo comparator
    Placebo treatment

    Placebo consisting of Ringer's lactate in matched volume to active drug is added to 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.

    Drug: Placebo treatment

  • Active comparator
    Methylnaltrexone treatment

    0.15 mg/kg methylnaltrexone will be dissolved in 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.

    Drug: Methylnaltrexone treatment

Interventions

  • DrugPlacebo treatment

    Active drug/placebo is given for the first 5 days of admission.

  • DrugMethylnaltrexone treatment

    Active drug/placebo is given for the first 5 days of admission.

06

What researchers measure

Primary outcomes

  1. Pancreatitis activity scoring system

    Difference in Pancreatitis activity scoring system (PASS) score between the methylnaltrexone group and the placebo group. The PASS-score is a weighted score of presence of organ failure, number of criterias of Systemic Inflammatory Response Syndrome fulfilled, abdominal pain (0-10), morphine equivalent dose (mg) and tolerance to solid food. Minimum value is 0 and higher score is equal to higher disease activity. Documentation for the PASS can be found on the following link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519418/

    Time frame: 48 hours after randomization

Secondary outcomes

  1. Pancreatitis activity scoring system

    Difference PASS scores between subgroups

    Time frame: 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit

  2. Difference in assessments of circulating proinflammatory marker

    C-Reactive Protein (mg/L)

    Time frame: 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit

  3. Difference in assessments of circulating pro- and anti-inflammatory markers

    Interleukin-6, Interleukin-8, Interleukin-18, Tumor necrosis factor alpha, Cluster of Differentiation 163 (serum) (all measured in pg/mL)

    Time frame: 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit

  4. Intestinal permeability

    Difference in intestinal permeability between subgroups using the oral polyethylene glycol 400/4000 test

    Time frame: From 48 to 72 hours after randomization

  5. Intestinal motility

    Difference in intestinal motility assessed by means of gut/colon transit using a CT-based radiopaque marker method between subgroups

    Time frame: 5 (+/- 1 day) after randomization

  6. Pancreatic complications

    Difference in pancreatic complications (e.g. edema, fluid collections and necrosis) assessed and quantified with contrast-enhanced CT

    Time frame: Day 5 (+/- 1 day) after randomization

  7. Pain intensity

    Difference between subgroups in pain intensity measured with the questionaire "modified Brief Pain Inventory short form" on visual analogue scale from 0-10 (0 is no pain and 10 is worst pain).

    Time frame: 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit

  8. Gut function (BSFS)

    Difference between subgroups in gut function assessed by The Bristol Stool Form Scale for assessment of stool frequency as well as stool consistency (scale from 1-7, where 1 is firmeste and 7 is softest)

    Time frame: 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit

  9. Gut function (GSRS)

    Difference between subgroups in gut function assessed by Gastrointestinal Symptom Rating Scale which is a disease-specific instrument of 15 items combined into five symptom clusters depicting reflux, abdominal pain, indigestion, diarrhea and constipation. The GSRS has a seven-point graded Likert-type scale, where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.

    Time frame: 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit

  10. Quantification of analgesics

    Difference between subgroups in given dose of analgesics (separated into opioids and non-opioids) based on name, administration route and dose

    Time frame: 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit

  11. Use of nutritional support

    Difference between subgroups in the use of nutritional support with registration of the used of either oral nutrition, enteral or parenteral nutrition.

    Time frame: 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit

  12. Days of hospitalization

    Difference between subgroups in days of hospitalization and days on intensive ward

    Time frame: Observation period starts from day of randomization and ends after 12 months or on the day of discharge which ever comes first

  13. Use of invasive treatment

    Difference between subgroups in use of invasive treatment (e.g. use of drain or surgery) measured in type and frequency of use

    Time frame: Observation period starts from day of randomization and ends after 12 months or on the day of discharge whichever comes first

  14. Mortality

    Difference between subgroups in mortality rate

    Time frame: Observation period starts from day of randomization and ends after 12 months or on the day of discharge whichever comes first

  15. Health resource utilization

    Difference in health resource utilization (measured in frequency and type of health services used (e.g. blood sample, MRI etc.) that can be converted into danish currency for economic analyses) between subgroups based on service codes (all services have unique service codes stored digitally).

    Time frame: Observation period starts from day of randomization and ends after 12 months or on the day of discharge whichever comes first

  16. Disease severity

    Disease severity classified by the revised Atlanta classification system in 3 levels; Mild, Moderate or Severe acute pancreatitis. (Mild acute pancreatitis, with no organ failure, local or systemic complications, Moderately severe acute pancreatitis is with presence of transient organ failure, local complications or exacerbation of co-morbid disease. Severe acute pancreatitis with persistent organ failure (\>48 h).

    Time frame: Observation period starts from day of randomization and ends after 12 months or on the day of discharge whichever comes first

07

Study locations

4 sites
  • Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital
    Aalborg, Jutland 9000, Denmark
  • Digestive Disease Center K, Bispebjerg University Hospital
    Bispebjerg, Denmark
  • Gastrounit, Hvidovre University Hospital
    Hvidovre, Denmark
  • Odense Pancreas Center
    Svendborg, Denmark
08

References and documents

Publications

  • Knoph CS, Cook ME, Fjelsted CA, Novovic S, Mortensen MB, Nielsen LBJ, Hansen MB, Frokjaer JB, Olesen SS, Drewes AM. Effects of the peripherally acting mu-opioid receptor antagonist methylnaltrexone on acute pancreatitis severity: study protocol for a multicentre double-blind randomised placebo-controlled interventional trial, the PAMORA-AP trial. Trials. 2021 Dec 19;22(1):940. doi: 10.1186/s13063-021-05885-3. PubMed 34924020 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Apr 2023, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 8, 2021
StartActual
May 14, 2021
Primary completionActual
Apr 9, 2023
CompletionActual
Apr 20, 2023
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04743570
Lead sponsor
Asbjørn Mohr Drewes
Collaborators
Odense University Hospital, Hvidovre University Hospital, University Hospital Bispebjerg and Frederiksberg
Responsible party
Asbjørn Mohr Drewes (Professor, Chief Physician, MD, PhD, DMSc, Aalborg University Hospital) — Sponsor-investigator
First posted
Feb 8, 2021
Start date
May 14, 2021
Primary completion
Apr 9, 2023
Completion
Apr 20, 2023
Last update
Apr 21, 2023

Study contacts

Asbjørn M. Drewes, Professor
study chair · Mech-Sense, Department of Medical Gastroenterology, Aalborg Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion